Obesity Medications, Especially GLP-1 Agonists, Show Broad Multisystem Benefits Beyond Weight Loss

Obesity is recognized as a complex gateway disease, significantly contributing to a cascade of metabolic, cardiovascular, reproductive, and neuropsychiatric conditions. While lifestyle interventions are foundational, pharmacotherapy is increasingly vital for effective disease management. Current understanding often focuses on weight reduction, yet a comprehensive view of how these medications impact various comorbidities, including type 2 diabetes, MASLD, and cardiovascular disease, is crucial. This review addresses the need to synthesize evidence on the multisystem benefits of approved and investigational obesity medications, highlighting effects beyond simple weight loss.